March 2015 in “Oncology Times” Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.
28 citations
,
October 1992 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” SIP is a better method for measuring hair growth accurately.
DOPE:DOPC liposomes can improve targeted cancer drug delivery, reducing side effects and increasing effectiveness.
November 2009 in “Eclética Química” The conclusion cannot be provided as the document content is not available.
February 2021 in “Pakistan Armed Forces Medical Journal” A rare skin condition usually found near the eyes was found on a farmer's scalp.
26 citations
,
January 1992 in “Carcinogenesis” TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
4 citations
,
February 2024 in “The Journal of Urology” Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.
The study successfully gathered a diverse group of 438 women to understand the prevalence of polycystic ovary syndrome, with most participants recruited online and at community fairs.
84 citations
,
March 2010 in “Infectious Disease Clinics of North America” The document concludes that rapid identification, isolation, and strict infection control are crucial to manage SARS outbreaks.
April 2018 in “Journal of Investigative Dermatology” Nonmelanoma skin cancers have higher levels of certain osteopontin variants than normal skin.
July 2024 in “Reactions Weekly” December 2024 in “Journal of Clinical Medicine” Assessing blood flow can improve skin graft success.
October 2025 in “Infection Control and Hospital Epidemiology” Standardized protocols are crucial for safe and infection-free platelet-rich plasma therapy.
44 citations
,
November 2016 in “Journal of The American Academy of Dermatology” The updated SALT II tool offers a more precise way to measure scalp hair loss.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
CAM practitioners in the eThekwini area are exploring ways to manage and diagnose Polycystic Ovarian Syndrome.
30 citations
,
February 2021 in “Journal of Medical Virology” TMPRSS2 affects COVID-19 severity and treatment options.
20 citations
,
October 2004 in “Journal of Pharmaceutical and Biomedical Analysis” Quick method to measure minoxidil in blood, accurate and useful for labs.
45 citations
,
May 2022 in “Biomedicines” Analyzing follicular fluid can help predict and improve outcomes for women with PCOS undergoing fertility treatments.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
April 2023 in “Journal of Investigative Dermatology” Krox20 (Egr2) is important for the function of epithelial stem cells.
87 citations
,
July 2018 in “Nursing Clinics of North America” PCOS is a common hormonal disorder in women, marked by symptoms like hair growth and menstrual issues, and requires personalized treatment.
May 2026 in “Scientific and Technical Bulletin оf State Scientific Research Control Institute of Veterinary Medical Products and Fodder Additives аnd Institute of Animal Biology” Zinc carbonate nanoparticles are not irritating or absorbed by the skin.
4 citations
,
January 2019 in “Clinical Chemistry” Diagnosing Polycystic Ovary Syndrome is hard due to varying symptoms, no set criteria, and the need for better tests and education.
5 citations
,
January 2014 in “Asian Journal of Chemistry” Researchers developed a quick and reliable method to test for betamethasone dipropionate and calcipotriol in ointments and drugs.
Finasteride may help reduce COVID-19 infection by altering a key gene.
SNP rs2479106 in the DENND1A gene may increase PCOS risk in Saudi Arabian females.
6 citations
,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
April 2025 in “Experimental Eye Research” The Oat mouse model shows mild retinal degeneration, useful for testing treatments.